Paratesticular rhabdomyosarcoma-Impact of locoregional approach on patient outcome: A report from the European paediatric Soft tissue sarcoma Study Group (EpSSG)

被引:13
|
作者
Rogers, Timothy N. [1 ]
De Corti, Federica [2 ]
Guillen Burrieza, Gabriela [3 ]
Guerin, Florent [4 ]
van Scheltinga, Sheila Terwisscha [5 ]
Snneulders, Naima [6 ]
Craigie, Ross [7 ]
Jenney, Meriel [8 ]
Kelsey, Anna [9 ]
Zanetti, Hada [10 ]
Coppadoro, Beatrice [10 ]
De Salvo, Gian Luca [11 ]
Bisogno, Gianni [10 ]
Martelli, Helene [4 ]
机构
[1] Univ Hosp Bristol NHS Fdn Trust Bristol, Dept Paediat Surg, Bristol, Avon, England
[2] Univ Hosp Padova, Dept Womans & Childs Hlth, Pediat Surg Unit, Padua, Italy
[3] Vall dHebron Univ Hosp, Dept Paediat Surg, Barcelona, Spain
[4] Hop Univ Paris Sud, Bicetre Hosp, Dept Paediat Surg, Le Kremlin Bicetre, France
[5] Prinses Maxima Ctr Kinderoncol, Dept Paediat Surg, Utrecht, Netherlands
[6] Great Ormond St Hosp Children NHS Fdn Trust, Dept Urol, London, England
[7] Royal Manchester Childrens Hosp, Dept Paediat Surg, Manchester, Lancs, England
[8] Childrens Hosp Wales Heath Pk, Dept Pediat Oncol, Cardiff, Wales
[9] Royal Manchester Childrens Hosp, Dept Pediat Histopathol, Manchester, Lancs, England
[10] Univ Padua, Dept Womens & Childrens Hlth, Hematol Oncol Div, Padua, Italy
[11] IRCCS Ist Oncol Veneto, Clin Trials & Biostat Unit, Padua, Italy
关键词
paratesticular; pediatric; rhabdomyosarcoma;
D O I
10.1002/pbc.28479
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background Paratesticular rhabdomyosarcoma (PT RMS) is rare compared to benign scrotal pathology. Inappropriate first surgery (InFS) required supplementary treatment to maintain excellent outcomes. Initial staging of regional lymph nodes is important. The aim of this study was to determine to what extent the quality of locoregional approach impacted on patient morbidity and survival. Design/methods Analysis was performed on all nonmetastatic PT RMS patients enrolled in the European paediatric Soft tissue sarcoma Study Group (EpSSG) RMS 2005 protocol. Aspects assessed were adherence to surgical guidelines and impact of protocol violations, relapse analysis, and survival outcomes. Results Analysis was performed on 237 patients, with median follow up of 67.1 months. Median age was 9.0 years. InFS occurred in 75 of 237 (32%) patients. InFS required intensified chemotherapy (10) and local therapy. After InFS, 61 required primary reexcision and five delayed surgery. Of 26 recurrences, the risk of relapse was higher in patients >= 10 years (21/26) and was mainly locoregional in 16 of 26 recurrences (+/- metastatic). Sixteen of 26 died with 14 of 16 patients >= 10 years. Nodal relapse neither occurred when N1 nodes were identified at diagnosis, nor after surgical staging. Five-year overall survival (OS) at age <10 years versus >= 10 years was 98.1 and 86.7%, respectively (P = .0013). Event-free survival (EFS) at age <10 years versus >= 10 years was 95.8 and 79.6%, respectively (P = .0004). OS and EFS did not highlight a significant difference in patients undergoing appropriate versus InFS (P = .8479,P = .2780, respectively). Conclusions InFS required intensified therapy to maintain excellent OS and EFS, so better anticipation of malignancy is required. Surgical staging of the retroperitoneal lymph nodes should be performed in patients >= 10 years old.
引用
收藏
页数:10
相关论文
共 50 条
  • [41] Delayed primary excision with subsequent modification of radiotherapy dose for intermediate-risk rhabdomyosarcoma: A report from the Children's Oncology Group Soft Tissue Sarcoma Committee
    Rodeberg, David A.
    Wharam, Moody D.
    Lyden, Elizabeth R.
    Stoner, Julie A.
    Brown, Kenneth
    Wolden, Suzanne L.
    Paidas, Charles N.
    Donaldson, Sarah S.
    Hawkins, Douglas S.
    Spunt, Sheri L.
    Arndt, Carola A.
    INTERNATIONAL JOURNAL OF CANCER, 2015, 137 (01) : 204 - 211
  • [42] Late events occurring five years or more after successful therapy for childhood rhabdomyosarcoma: a report from the Soft Tissue Sarcoma Committee of the Children's Oncology Group
    Sung, L
    Anderson, JR
    Donaldson, SS
    Spunt, SL
    Crist, WM
    Pappo, AS
    EUROPEAN JOURNAL OF CANCER, 2004, 40 (12) : 1878 - 1885
  • [43] Treatment Efficiency, Outcome and Surgical Treatment Problems in Patients Suffering From Localized Embryonal Bladder/Prostate Rhabdomyosarcoma: A Report From the Cooperative Soft Tissue Sarcoma Trial CWS-96
    Seitz, Guido
    Dantonello, Tobias M.
    Int-Veen, Christoph
    Blumenstock, Gunnar
    Godzinski, Jan
    Klingebiel, Thomas
    Schuck, Andreas
    Leuschner, Ivo
    Koscielniak, Ewa
    Fuchs, Joerg
    PEDIATRIC BLOOD & CANCER, 2011, 56 (05) : 718 - 724
  • [44] Metabolic response as assessed by 18F-fluorodeoxyglucose positron emission tomography-computed tomography does not predict outcome in patients with intermediate- or high-risk rhabdomyosarcoma: A report from the Children's Oncology Group Soft Tissue Sarcoma Committee
    Harrison, Douglas J.
    Chi, Yueh-Yun
    Tian, Jing
    Hingorani, Pooja
    Mascarenhas, Leo
    McCowage, Geoffrey B.
    Weigel, Brenda J.
    Venkatramani, Rajkumar
    Wolden, Suzanne L.
    Yock, Torunn I.
    Rodeberg, David A.
    Hayes-Jordan, Andrea A.
    Teot, Lisa A.
    Spunt, Sheri L.
    Meyer, William H.
    Hawkins, Douglas S.
    Shulkin, Barry L.
    Parisi, Marguerite T.
    CANCER MEDICINE, 2021, 10 (03): : 857 - 866
  • [45] Reduction of Cyclophosphamide Dose for Patients With Subset 2 Low-Risk Rhabdomyosarcoma Is Associated With an Increased Risk of Recurrence: A Report From the Soft Tissue Sarcoma Committee of the Children's Oncology Group
    Walterhouse, David O.
    Pappo, Alberto S.
    Meza, Jane L.
    Breneman, John C.
    Hayes-Jordan, Andrea
    Parham, David M.
    Cripe, Timothy P.
    Anderson, James R.
    Meyer, William H.
    Hawkins, Douglas S.
    CANCER, 2017, 123 (12) : 2368 - 2375
  • [46] Does body mass index at diagnosis or weight change during therapy predict toxicity or survival in intermediate risk rhabdomyosarcoma? A report from the Children's Oncology Group soft tissue sarcoma committee
    Burke, Megan E.
    Lyden, Elizabeth R.
    Meza, Jane L.
    Ladas, Elena J.
    Dasgupta, Roshni
    Wiegner, Ellen A.
    Arndt, Carola A. S.
    PEDIATRIC BLOOD & CANCER, 2013, 60 (05) : 748 - 753
  • [47] Survival outcomes of patients with localized FOXO1 fusion-positive rhabdomyosarcoma treated on recent clinical trials: A report from the Soft Tissue Sarcoma Committee of the Children's Oncology Group
    Heske, Christine M.
    Chi, Yueh-Yun
    Venkatramani, Rajkumar
    Li, Minjie
    Arnold, Michael A.
    Dasgupta, Roshni
    Hiniker, Susan M.
    Hawkins, Douglas S.
    Mascarenhas, Leo
    CANCER, 2021, 127 (06) : 946 - 956
  • [48] Myogenin, AP2β, NOS-1, and HMGA2 Are Surrogate Markers of Fusion Status in Rhabdomyosarcoma A Report From the Soft Tissue Sarcoma Committee of the Children's Oncology Group
    Rudzinski, Erin R.
    Anderson, James R.
    Lyden, Elizabeth R.
    Bridge, Julia A.
    Barr, Frederic G.
    Gastier-Foster, Julie M.
    Bachmeyer, Karen
    Skapek, Stephen X.
    Hawkins, Douglas S.
    Teot, Lisa A.
    Parham, David M.
    AMERICAN JOURNAL OF SURGICAL PATHOLOGY, 2014, 38 (05) : 654 - 659
  • [49] Comparison of outcomes based on treatment algorithms for rhabdomyosarcoma of the bladder/prostate: combined results from the Children's Oncology Group, German Cooperative Soft Tissue Sarcoma Study, Italian Cooperative Group, and International Society of Pediatric Oncology Malignant Mesenchymal Tumors Committee
    Rodeberg, David A.
    Anderson, James R.
    Arndt, Carola A.
    Ferrer, Fernando A.
    Raney, Richard Beverly
    Jenney, Meriel E.
    Brecht, Ines B.
    Koscielniak, Ewa
    Carli, Modesto
    Bisogno, Gianni
    Oberlin, Odile
    Rey, Annie
    Ullrich, Fred
    Stevens, Michael C. G.
    Meyer, William H.
    INTERNATIONAL JOURNAL OF CANCER, 2011, 128 (05) : 1232 - 1239
  • [50] Outcome of patients with localized orbital sarcoma who relapsed following treatment on Intergroup Rhabdomyosarcoma Study Group (IRSG) Protocols-III and -IV, 1984-1997: A report from the Children's Oncology Group
    Raney, Beverly
    Huh, Winston
    Hawkins, Douglas
    Hayes-Jordan, Andrea
    Million, Lynn
    Rodeberg, David
    Teot, Lisa
    Anderson, James
    PEDIATRIC BLOOD & CANCER, 2013, 60 (03) : 371 - 376